Edwards Lifesciences posts Q3 growth and lifts 2026 sales outlook
Edwards Lifesciences reported third‑quarter 2026 sales of $1.72 billion, up 10.5% year‑over‑year (11.2% on a constant‑currency basis). GAAP EPS was $0.53 and adjusted EPS $0.80, a 19% increase. The company raised its full‑year 2026 sales growth guidance to approximately 11.5% and lifted TAVR growth guidance to 9.0‑9.5% and TMTT sales guidance to $780‑$790 million, with adjusted EPS guidance now $2.97‑$3.05.
Why it matters
The higher sales and earnings guidance signals stronger demand for Edwards’ TAVR and TMTT products, which could support the stock price and affect analyst forecasts. The raised outlook also implies higher cash flow potential for shareholders.
Key facts
- 1Q3 sales grew 10.5% to $1.72 billion (11.2% constant‑currency)【4】 sec.gov
- 2Q3 TAVR sales grew 8.0% to $1.24 billion (8.8% constant‑currency)【4】 sec.gov
- 3Q3 TMTT sales grew 44.0% to $207 million (45.6% constant‑currency)【4】 sec.gov
- 4GAAP EPS for Q3 was $0.53【4】 sec.gov
- 5Adjusted EPS for Q3 was $0.80, up 19% YoY【4】 sec.gov
- 6Full‑year 2026 sales growth guidance increased to approximately 11.5% from 10‑11%【4】 sec.gov
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.